Latest news with #InsmedInc
Yahoo
18-06-2025
- Business
- Yahoo
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area. A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
18-06-2025
- Business
- Yahoo
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area. A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Insmed (INSM) Soars After Raising $650 million
We recently published a list of . In this article, we are going to take a look at where Insmed Inc. (NASDAQ:INSM) stands against other best-performing stocks on Wednesday. Insmed jumped for a second day on Wednesday, adding 7.75 percent to close at $97.98 apiece following plans to raise $650 million through the issuance of more shares. In a copy of the prospectus, Insmed Inc. (NASDAQ:INSM) said proceeds from the offer will be used to fund the continued research and development, pre-commercial, and commercialization of its drug candidates brensocatib, Arikayce, treprostinil palmitil inhalation powder (TPIP), and INSI201, among others. The remaining balance will be allocated for general corporate purposes, including business expansion. Additionally, Insmed Inc. (NASDAQ:INSM) granted its underwriters the option to purchase up to an additional $97.5 million of its common stock. The fundraising program followed Insmed Inc.'s (NASDAQ:INSM) promising results from the phase 2 trial of its pulmonary arterial hypertension (PAH) treatment, TPIP. According to the company, the phase 2 trial achieved its primary and secondary goals for the treatment of reducing blood pressure in the lungs and improving exercise capacity in patients. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Following the announcements, four investment companies, namely BofA Securities, RBC, Morgan Stanley, and Mizuho, gave a 'buy' recommendation and 'overweight' rating on its stock at a price target ranging from $102 to $110. Overall, INSM ranks 10th on our list of best-performing stocks on Wednesday. While we acknowledge the potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Economic Times
10-06-2025
- Business
- Economic Times
US Stock market future today: Dow, S&P 500 and Nasdaq futures flat as US-China trade talks continue and investors await key CPI inflation data
Major U.S. Indices & Futures (Premarket – June 10, 2025) Index/Future Status Dow Jones Futures Slightly lower (~–0.06 %) S&P 500 Futures Flat to marginally positive (+0.00 %) Nasdaq Futures Up around +0.07 % (tech‑led optimism) Premarket Top Gainers Insmed Inc. (INSM) : +17.1 % : +17.1 % Casey's General Stores (CASY) : +10.2 % : +10.2 % Summit Therapeutics (SMMT) , Circle Internet Group (CRCL) , IDACORP (IDA) : each up ≥3 % , , : each up ≥3 % From broader premarket screen: Evogene (EVGN) : +164 % Magic Empire Global (MEGL) : +128 % Carisma Therapeutics (CARM) : +77 % Premarket Top Losers United Therapeutics (UTHR) : –12.9 % : –12.9 % J.M. Smucker Co. (SJM) : –7.9 % : –7.9 % Others from broader list: Unicycive Therapeutics (UNCY) : –45 % Baiya International (BIYA) : –40 % Calavo Growers (CVGW) : –14 % Yesterday's Regular Session Highlights (June 9, 2025) S&P 500 : +0.09 %, closing around 6,005.9 : +0.09 %, closing around Dow Jones : Flat, around 42,761.8 : Flat, around Nasdaq Composite: +0.31 %, near 19,591.2 Helmerich & Payne : +5.43 % : +5.43 % Vornado Realty Trust : +5.26 % : +5.26 % Regeneron : +5.02 % : +5.02 % AMD : +4.72 % : +4.72 % Tesla: +4.36 % Live Events Edison International : –8.05 % : –8.05 % PG&E : –6.60 % : –6.60 % Universal Health Services : –6.18 % : –6.18 % Intuitive Surgical : –5.58 % : –5.58 % Mosaic: –5.01 % Why are US-China trade talks causing market caution? Market Overview Futures and ETFs are mostly subdued , with S&P‑500‑tracking SPY nearly flat, Dow‑tracking DIA dipping slightly, and QQQ (Nasdaq‑100) modestly positive. , with S&P‑500‑tracking SPY nearly flat, Dow‑tracking DIA dipping slightly, and QQQ (Nasdaq‑100) modestly positive. This calm premarket behavior reflects investor caution amid day‑two U.S.–China trade talks in London. What happened to Chinese stocks amid the talks? How are small businesses reacting in the US? Key Drivers U.S.–China Trade Negotiations: Futures show minimal movement, echoing mixed signs of progress as both sides look to ease export controls in return for rare-earth supply concessions. Precedence of U.S. Inflation Data: The market is eagerly awaiting the Consumer Price Index on Wednesday, which could significantly influence rate expectations. Sector-Specific Movers: Growth in semiconductor stocks like TSMC is propping up the tech-heavy Nasdaq futures. Apple fell slightly after its WWDC updates, while Meta's AI announcement also captured investor attention What are analysts watching next in the stock market? What's the big takeaway for investors right now? FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US stock market futures traded in a narrow range on Tuesday, with investors cautiously watching the second day of US-China trade talks unfold. After a positive start to discussions, traders are waiting to see if any concrete progress will be made, particularly around rare earth minerals access, which has become a key sticking tied to the Dow Jones Industrial Average (YM=F), S&P 500 (ES=F), and Nasdaq 100 (NQ=F) were mostly flat in early morning trading. This hesitant tone reflected the market's uncertainty about whether this round of trade negotiations will lead to any breakthroughs — or just more delays.: Boeing +3.07 %, Dow Inc +2.87 %, Intel +1.94 %, Amazon +1.51 %, Disney +1.49 %: Travelers –2.19 %, Nike –1.45 %, Apple –1.37 %, Visa –1.04 %, 3M –0.93 %: Regeneron +5.02 %, AMD +4.72 %, Tesla +4.36 %, Qualcomm +4.12 %, Texas Instruments +3.49 %: Intuitive Surgical –5.58 %, T‑Mobile –3.28 %, ADP –2.60 %, Netflix –1.46 %, Apple –1.37 %The latest round of US-China trade negotiations resumed in London on Tuesday morning. Following an encouraging first day, both sides are now grappling with more difficult issues — including the US push for better access to China's rare earth mineral supply chain. These minerals are critical for technology, electric vehicles, and defense White House officials sounded optimistic on Monday, President Trump later warned that "China's not easy" to deal with. That mixed messaging has left investors on edge. The last few years have shown how quickly tariffs and tensions between the US and China can send global markets of Tuesday's trade discussions, Chinese stocks saw a sharp decline, reflecting nervous sentiment among local investors. According to Bloomberg, Fu Shifeng, investment director at Cheng Zhou Investment, commented that 'the market is too sensitive… people seem to be speculating that the talks didn't go well.'This sudden drop suggests that optimism about a deal is thin, and the lack of transparency around the talks is adding to the volatility. With no clear signals yet, traders are bracing for all the trade uncertainty, a small glimmer of positivity came from the NFIB (National Federation of Independent Business). Their May survey showed a rise in small-business optimism, the first increase since September. The report cited the current trade truce with China as one reason behind the boost in that optimism is also being tested. Concerns are growing over President Trump's massive tax-and-spending proposals, which many business owners feel could raise the national debt and increase next big moment for investors is the release of the May Consumer Price Index (CPI) data, expected on Wednesday. This inflation report is crucial, especially as the Fed continues weighing future interest rate predict that price pressures picked up in May, possibly fueled by trade uncertainty and higher import costs. A hotter-than-expected CPI reading could spook markets further, especially tech stocks which are more sensitive to interest rate are walking a tightrope. US-China trade talks have the potential to ease global tensions and lift investor sentiment — but only if they show meaningful progress. At the same time, inflation data, US fiscal policy concerns, and overseas market volatility are keeping things now, investors are taking a wait-and-see approach. Futures are flat, volatility is rising in Asia, and every headline from London could move the needle. The next 24–48 hours could be critical in setting the tone for the markets this US-China talks and inflation worries are keeping stock futures flat and investors CPI report could reveal rising inflation, which may affect Fed rate decisions and stock market direction.
